Literature DB >> 16785213

Antagonist treatment of opioid withdrawal translational low dose approach.

Paolo Mannelli1, Edward Gottheil, Elisabeth J Van Bockstaele.   

Abstract

Although antagonist drugs are receiving increasing attention in the treatment of opioid withdrawal, the mechanisms of interaction of opiate agonists and antagonists remain largely to be investigated. We focused on the effects of very low quantities of opiate antagonists, following the clinical indication of their potential utility in detoxification. Upon reviewing the evidence on the administration of small doses of naloxone and naltrexone in the presence of agonist drugs, the effects of low-dose naltrexone during opiate administration and withdrawal are described. The application of a translational methodology allowed completing the clinical design with behavioral and cellular information obtained from a specifically developed animal model. The initial results indicate that low doses of naltrexone may help reducing the manifestation of opioid withdrawal, offer suggestions for further investigations and confirm the utility of a translational research approach to the clinical neurobiology of drug addiction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785213     DOI: 10.1300/J069v25n02_01

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  4 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

3.  Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil
Journal:  Addict Biol       Date:  2008-08-19       Impact factor: 4.280

4.  Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database.

Authors:  Guttorm Raknes; Lars Småbrekke
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-03-29       Impact factor: 2.890

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.